<DOC>
	<DOCNO>NCT01966913</DOCNO>
	<brief_summary>High-dose chemotherapy autologous hematopoietic stem-cell transplantation standard salvage treatment use adult germ cell tumor ( Einhorn et al , J Clin Oncol 2007 ) . Disease prognosis follow 1 2 intensified combination etoposide - carboplatin +/- ifosfamide depend patient 's performance status ( PS ) inclusion prior sensitivity disease cisplatin . A poor PS and/or refractory cisplatin suggest high toxicity bad prognosis . However , predictive factor response high-dose chemotherapy include chemo-sensitivity phase semi-intensive chemotherapy exclude platinum compound ( epirubicin - paclitaxel ) , still allow stem-cell harvest . The use chemotherapy combination induce response one third patient treat disease progression TAXIF I study . The strategy test TAXIF II study , complete inclusion 45 patient close May 2008 . Results TAXIF II study , currently analyze ; support hypothesis prioritarily treat patient sensitive relapsed disease time high-dose administration . A combination semi-intensive sequential ICE type chemotherapy plus bevacizumab use highly refractory patient . A 5 month nearly complete response achieve . Indeed , overexpression VEGF ( Vascular Endothelial Growth Factor ) identify independent risk factor patient germ cell tumor . Therefore , treatment strategy use inductive chemotherapy follow , case response , double intensification therapy combination VEGF treatment , could interest approach patient poor prognosis germ cell tumor . The aim phase I/II trial ass feasibility Bevacizumab - ICE ( Ifosfamide-Carboplatin-Etoposide ) high dose combination support autologous hematopoietic stem cell two intensive consecutive cycle ( `` tandem '' intensification ) patient poor prognosis germ cell tumor non refractory front-line mobilization chemotherapy use two half intensify consecutive combination Epirubicin-Paclitaxel .</brief_summary>
	<brief_title>Salvage Chemotherapy Poor Prognosis Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patient age 18 year old sign informed consent form . Germ cell tumor gonadal origin , extragonadal , retroperitoneal primary mediastinal , exclude CNS tumor . Relapsed , refractory completely refractory disease . The patient must receive : For relapsed patient , two line standard chemotherapy ( BEP EP firstline treatment , VeIP VIP secondline treatment ) For refractory completely refractory patient , one line standard chemotherapy ( BEP EP ) First extragonadal tumor relapse Normal laboratory test level usually require intensive treatment Performance status &lt; 2 . Life expectancy â‰¥ 3 month . Brain metastasis Lesions grow teratoma Cardiovascular disease , uncontrolled hypertension History transient ischemic attack All contraindication bevacizumab treatment Nonhealing wound , active peptic ulcer bone fracture know allergy bevacizumab excipients know allergy chemotherapy include Cremophor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Germ Cell Tumors</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>salvage therapy</keyword>
</DOC>